The Brand Name GONABLOK Has Generic Salt :: Danazol 

GONABLOK  Is From Company Win-Medicare Priced :: Rs. 356.55

GONABLOK have Danazol is comes under Sub class Androgens and Anti Androgens of  Main Class Endocrine,Steroid Hormones , Metabolic System

Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System  Sub Medicine Class :: Androgens and Anti Androgens 

Indications for Drugs ::

Endometriosis, Benign breast disorders, Gynaecomastia, Hereditary angioedema, Menorrhagia.

Drug Dose ::

Adult: PO: 200-800 mg/day in 2 divided doses for 3-6 mth, up to 9 mth if needed. It is recommended that danazol therapy in adult females should start on the first day of the menstrual cycle with an adjustment of dosage made subsequently to achieve amenorrhoea or the desired effect. In endometrosis : The initial dose is 400 mg daily usually continued for 6 months. If symptoms do not resolve, the dose can be increased to 800 mg daily but the total course should not exceed 9 months. Benign breast disease: Severe cyclical mastalgia. The recommended initial dose for severe cyclical mastalgia is 200-300 mg daily for 3-6 month. In several studies, the initial dose was either 200 mg or 300 mg daily, which was reduced after either 1 or 2 months if a clinically useful response had occurred. Benign, multiple or recurrent breast disease: The recommended initial dose for this indication is 300 mg daily for 3-6 months. Menorrhagia: In menorrhagia, daily doses of 100-200 mg have been found effective but 200 mg daily is usually sufficient to reduce menstrual blood flow to acceptable levels. The recommended initial dose is 200 mg daily for 3 months. Gynecomastia: Adults, 300-600 mg daily. Adolescents, 200-300 mg daily. Preoperative thinning of the endometrium before hysteroscopic endometrial ablation: Danazol induces endometrial atrophy and is currently recommended at doses of 400-800 mg daily for up to 3 months preoperatively.

Contraindication ::

Hypersensitivity, pregnancy, lactation, porphyria, thromboembolic disorders; undiagnosed genital bleeding, markedly impaired renal, cardiac or hepatic dysfunction.

Drug Precautions ::

Danazol may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, or cardiac or renal dysfunction, polycythemia and hypertension require careful observation. Use with caution in patients with diabetes mellitus. Since hepatic dysfunction manifested by modest increases in serum transaminases levels has been reported in patients treated with Danazol, periodic liver function tests should be performed Administration of danazol has been reported to cause exacerbation of the manifestations of acute intermittent porphyria.

Drug Side Effects ::

Oedema, wt gain, sweating, acne, hirsutism, flushing, oily skin or hair, deepening of the voice, clitoral hypertrophy, amenorrhoea, hepatic dysfunction, CNS or GI disturbances, benign intracranial hypertension, reduction in breast size, visual disturbances, elevated LFT values. Other adverse effects: Include menstrual disturbances, hypo-estrogenic symptoms, such as flushing, vaginal dryness and irritation and a modest reduction of spermatogenesis in the male. Maculopapular, petechial, purpuric and urticarial rashes have been reported. Cardiovascular reactions may include exacerbation of hypertension, palpitations and tachycardia. Various psychological reactions such as increased appetite, emotional lability, anxiety, depression, nervousness, changes in libido, dizziness, vertigo, nausea, headache and fatigue have been described. Potentially Fatal: Thromboembolic events and fatal strokes have been reported.

Pregnancy category ::

5

Drug Mode of Action ::  

Danazol suppresses the pituitary-ovarian axis by reducing the release of follicle-stimulating hormone and luteinizing hormone. This causes the regression and atrophy of endometrial tissue, decreases growth rate of abnormal breast tissue and reduces attacks in hereditary angioedema.

Drug Interactions ::

Increased serum levels of ciclosporin, warfarin, carbamazepine and tacrolimus. Potentially Fatal: Increased incidence of insulin resistance in diabetic patients.